Results 51 to 60 of about 19,663 (194)
Crizotinib: A comprehensive review
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as crizotinib. The integration of crizotinib into standard
Vanita Noronha +4 more
core +1 more source
Purpose: Our study aimed to provide data on effectiveness, safety of crizotinib treatment, brain metastases, progression patterns, and sequential therapy beyond crizotinib treatment in patients with advanced ALK-positive NSCLC in China.Methods: We ...
Chang Liu +23 more
doaj +1 more source
This study developed an optimized multiplex RT‐MIRA assay for the simultaneous detection of EML4‐ALK variants, achieving single‐copy sensitivity. Unexpectedly, during the development of the reaction system, we discovered a “low‐concentration enhancement effect,” where reducing primer or probe concentrations within a specific range markedly improved ...
Xiao‐Dong Ren +10 more
wiley +1 more source
Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content
Ferroptosis is a specific form of cell death characterized by excessive accumulation of cellular lipid peroxides. Ferroptosis is closely associated with various diseases, inhibition of which may help alleviate multi-organ injury caused by ischemia ...
Si-Yu Cen +11 more
doaj +1 more source
Background Non–small cell lung cancer (NSCLC) accounts for approximately 80–85% of all lung cancers and is usually diagnosed at an advanced stage with poor prognosis. Targeted therapy has produced unprecedented outcomes in patients with NSCLC as a number
Xuanxuan Dai +11 more
doaj +1 more source
Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real‐world data of ALK TKIs remain a major concern.
Yurong Wang +5 more
doaj +1 more source
LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis
Background: Crizotinib is a microtubule-related protein-4-anaplastic lymphoma kinase (EML4-ALK) multi-target tyrosine kinase inhibitor applied in the treatment of ALK-rearranged NSCLC.
Meiling Zhang +6 more
doaj +1 more source
Nail Toxicities Associated With Anticancer Therapies in Children
ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley +1 more source
Clinical Efficacy of Crizotinib in Advanced ALK Positive Non-small Cell Lung Cancer
Background and objective The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer.
Jing ZHAO +3 more
doaj +1 more source
Oxaziridines: Versatile Reagents in Modern Organic Synthesis
Being capable of transferring an O atom and N‐group/atom, oxaziridines are considered multitasking agents. These are employed for diverse organic transformations, such as epoxidation of olefins, α‐ and γ‐hydroxylation/amination of carbonyl compounds, oxidation of sulfides, [3+2]cycloaddition with unsaturated systems.
Ajeet Chandra +2 more
wiley +1 more source

